Reviva Pharmaceuticals Holdings, Inc. (RVPH)
OTC PINK OTC PINK Primary Summary
Reviva Pharmaceuticals: Upcoming Events May Generate Excitement, But Cash Is Low
Reviva Pharmaceuticals aims to improve schizophrenia treatment with Brilaroxazine, showing promising Phase 3 data but needing funding for a second trial to meet FDA requirements. Reviva should announce open label safety and biomarker efficacy data from its previous Phase 3 trial any day now. The company faces financial challenges, requiring either dilution or a partnership to fund the next Phase 3 trial and continue operations.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH
NEW YORK, NY / ACCESSWIRE / June 1, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Reviva Pharmaceuticals Holdings, Inc. ("Reviva" or the "Company") (NASDAQ:RVPH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Reviva Pharmaceuticals Holdings, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| ABB Alexander Bjornager Bonde Danske Bank A/S | 7 | $5 | $4.06 | -$0.94 | -18.8% |
 Anthony Scaramucci SkyBridge Capital II LLC | 592,079 | $432,039.99 | $343,405.82 | -$88,634.17 | -20.52% |
| SE Sima Elimelech Activest Wealth Management | 50 | $36.5 | $29.21 | -$7.29 | -19.97% |
 Kevin Bresler TD Waterhouse Canada Inc. | 625 | $456.25 | $353.12 | -$103.13 | -22.6% |
| LSJ Laddi Singh Jhuty NRI Wealth Management LC | 569 | $58,607 | $317.5 | -$58,289.5 | -99.46% |
Reviva Pharmaceuticals Holdings, Inc. (RVPH) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Reviva Pharmaceuticals Holdings, Inc. ever had a stock split?
Reviva Pharmaceuticals Holdings, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Laxminarayan Bhat CEO | OTC PINK Exchange | 76152G209 CUSIP |
| US Country | 14 Employees | - Last Dividend | 9 Mar 2026 Last Split | 18 Oct 2018 IPO Date |
Overview
Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and potential commercialization of innovative therapeutics for a variety of diseases with unmet medical needs. Focusing on central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases, Reviva aims to bring transformative treatment options to patients. Founded in 2018, the company operates out of Cupertino, California, reflecting its commitment to advancing medical science and enhancing patient care.
Products and Services
Brilaroxazine (RP5063): This is Reviva’s lead product candidate, currently in Phase III clinical trials for the treatment of schizophrenia. It has also completed Phase I clinical trials targeting a range of conditions, including bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. Brilaroxazine represents a promising advancement in treating various serious and challenging disorders, showing Reviva's broad focus and innovative approach in developing therapeutics.
RP1208: Still in the pre-clinical development phase, RP1208 is being explored for its potential in treating depression and obesity. This investigative approach signifies Reviva’s continued commitment to addressing critical areas of unmet medical need, leveraging novel mechanisms of action to potentially deliver improved outcomes for patients suffering from these conditions.
